Nakazato Masamitsu
Division of Neurology, Respirology, Endocrinology and Metabolism, Department of Internal Medicine, University of Miyazaki.
Nihon Rinsho. 2011 May;69(5):918-22.
Glucagon-like peptide 1 (GLP-1) is a peptide produced in the endocrine L cells of the distal intestine. GLP-1(7-36)NH2 is a major molecular form that stimulates insulin release, reduces food intake, and has a potential to promote beta-cell regeneration. We have developed a device for intranasal application of GLP-1(7-36)NH2 and completed a double-blind clinical trial of intranasal administration of GLP-1(7-36)NH2 to 26 type II diabetic patients. Intranasal administration of GLP-1 increased its plasma level, stimulated postprandial insulin release, and suppressed glucagon release. Two-week intranasal administration of GLP-1 just before meals significantly decreased serum glycoalbumin level and significantly increased 1,5-AG (1,5-anhydro-D-glucitol) level. Hypoglycemia was not found through this study. Intranasal GLP-1 administration using the novel device and medication improved glycemic control in type 2 diabetic patients without any adverse effects.
胰高血糖素样肽1（GLP-1）是一种在远端肠道的内分泌L细胞中产生的肽。GLP-1(7-36)NH₂一种主要分子形式，可刺激胰岛素释放、减少食物摄入量，并具有促进β细胞再生的潜力。我们开发了一种用于鼻内施用GLP-1(7-36)NH₂的装置，并完成了一项对26名II型糖尿病患者进行鼻内施用GLP-1(7-36)NH₂的双盲临床试验。鼻内施用GLP-1可提高其血浆水平，刺激餐后胰岛素释放，并抑制胰高血糖素释放。在饭前两周鼻内施用GLP-1可显著降低血清糖化白蛋白水平，并显著提高1,5-AG（1,5-脱水-D-葡萄糖醇）水平。通过本研究未发现低血糖情况。使用新型装置和药物进行鼻内GLP-1给药可改善2型糖尿病患者的血糖控制，且无任何不良反应。
